Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Radix bupleuri aqueous extract is a botanical preparation derived from the dried root of *Bupleurum* species, most commonly *Bupleurum chinense* or related sources used in traditional East Asian medicine. Based on the provided publication, it is being investigated preclinically for schizophrenia, where oral administration in an MK-801 mouse model was reported to reduce schizophrenia-like behaviors, decrease hippocampal inflammatory signaling and microglial activation, normalize dopamine and serotonin abnormalities, increase synaptic markers and brain-derived neurotrophic factor, improve intestinal barrier integrity, and alter gut microbial composition. Its pharmacology appears pleiotropic rather than driven by a single defined molecular target, with activity consistent with a multi-component botanical extract exerting anti-inflammatory, neuroprotective, and microbiome-modulating effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on radix bupleuri aqueous extract.